CN103724339B - 二氢嘧啶衍生物的晶型 - Google Patents

二氢嘧啶衍生物的晶型 Download PDF

Info

Publication number
CN103724339B
CN103724339B CN201310446506.0A CN201310446506A CN103724339B CN 103724339 B CN103724339 B CN 103724339B CN 201310446506 A CN201310446506 A CN 201310446506A CN 103724339 B CN103724339 B CN 103724339B
Authority
CN
China
Prior art keywords
crystal form
present
ray powder
powder diffraction
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310446506.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103724339A (zh
Inventor
张英俊
任青云
刘辛昌
王超磊
王天明
S·戈尔德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Priority to CN201310446506.0A priority Critical patent/CN103724339B/zh
Priority to CN201510364423.6A priority patent/CN104945394B/zh
Publication of CN103724339A publication Critical patent/CN103724339A/zh
Application granted granted Critical
Publication of CN103724339B publication Critical patent/CN103724339B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201310446506.0A 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型 Active CN103724339B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201310446506.0A CN103724339B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型
CN201510364423.6A CN104945394B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201210369019 2012-09-27
CN2012103690194 2012-09-27
CN201210369019.4 2012-09-27
CN201310117076.8 2013-04-04
CN2013101170768 2013-04-04
CN201310117076 2013-04-04
CN201310446506.0A CN103724339B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510364423.6A Division CN104945394B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Publications (2)

Publication Number Publication Date
CN103724339A CN103724339A (zh) 2014-04-16
CN103724339B true CN103724339B (zh) 2015-10-14

Family

ID=50355923

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201310446506.0A Active CN103724339B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型
CN201310445326.0A Pending CN103694234A (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型
CN201510364423.6A Active CN104945394B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201310445326.0A Pending CN103694234A (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型
CN201510364423.6A Active CN104945394B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Country Status (20)

Country Link
US (1) US9403814B2 (https=)
EP (1) EP2900664B1 (https=)
JP (1) JP6310923B2 (https=)
KR (1) KR20150060610A (https=)
CN (3) CN103724339B (https=)
AU (1) AU2013324779B2 (https=)
BR (1) BR112015002979B8 (https=)
CA (1) CA2881260C (https=)
DK (1) DK2900664T3 (https=)
ES (1) ES2660642T3 (https=)
HU (1) HUE037285T2 (https=)
MX (1) MX362829B (https=)
MY (1) MY171497A (https=)
PL (1) PL2900664T3 (https=)
PT (1) PT2900664T (https=)
RU (1) RU2646599C2 (https=)
SG (1) SG11201500145TA (https=)
TW (1) TWI561520B (https=)
WO (1) WO2014048355A1 (https=)
ZA (1) ZA201500290B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015002954A (es) * 2012-09-10 2015-06-05 Hoffmann La Roche Nuevas 6-aminoacido-heteroarilhidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b.
ES2794639T3 (es) * 2015-11-04 2020-11-18 Qilu Pharmaceutical Co Ltd Forma cristalina, método de preparación y compuesto intermedio de compuesto con anillo dihidropirido
WO2017198201A1 (en) * 2016-05-19 2017-11-23 Sunshine Lake Pharma Co., Ltd. Crystalline form, salt and complex of dihydropyrimidine derivative, and uses thereof in medicine
CN107722109B (zh) * 2016-08-11 2020-12-18 广东东阳光药业有限公司 作为丙型肝炎病毒抑制剂的晶型
US9856232B1 (en) * 2017-06-20 2018-01-02 King Saud University Dihydropyrimidinone derivatives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777606A (zh) * 2003-04-22 2006-05-24 索尔瓦药物有限公司 4－(4－反式－羟基环己基)氨基－2－苯基－7H－吡咯并[2,3d]嘧啶氢甲磺酸盐及其多晶型物
CN101328171A (zh) * 2007-06-18 2008-12-24 张中能 一种溴苯基-取代的噻唑二氢嘧啶
CN101328169A (zh) * 2007-06-18 2008-12-24 张中能 一种乙氧碳酰基-取代噻唑二氢嘧啶
WO2010069147A1 (zh) * 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154820A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
CN101328170B (zh) 2007-06-18 2011-09-14 张中能 一种氟苯基-取代噻唑二氢嘧啶
CN101744823B (zh) * 2008-12-17 2013-06-19 广东东阳光药业有限公司 一种二氢嘧啶类化合物的固体分散体及其药用制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777606A (zh) * 2003-04-22 2006-05-24 索尔瓦药物有限公司 4－(4－反式－羟基环己基)氨基－2－苯基－7H－吡咯并[2,3d]嘧啶氢甲磺酸盐及其多晶型物
CN101328171A (zh) * 2007-06-18 2008-12-24 张中能 一种溴苯基-取代的噻唑二氢嘧啶
CN101328169A (zh) * 2007-06-18 2008-12-24 张中能 一种乙氧碳酰基-取代噻唑二氢嘧啶
WO2010069147A1 (zh) * 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Xue-Yan Wang,等.In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovirdipivoxil-resistant HBV mutations.《Antiviral Therapy》.2012,第17卷第793-803页. *
赵国明,等.新型二氢嘧啶类化合物的合成及其抗乙型肝炎病毒活性研究.《中国科学:生命科学》.2011,第41卷(第10期),第971-977页. *

Also Published As

Publication number Publication date
CN103694234A (zh) 2014-04-02
BR112015002979B1 (pt) 2020-12-22
AU2013324779A1 (en) 2015-02-05
MX2015004115A (es) 2016-01-20
PT2900664T (pt) 2018-03-02
HUE037285T2 (hu) 2018-08-28
MX362829B (es) 2019-02-14
WO2014048355A1 (en) 2014-04-03
BR112015002979B8 (pt) 2022-03-03
CN103724339A (zh) 2014-04-16
DK2900664T3 (en) 2018-02-05
EP2900664A1 (en) 2015-08-05
RU2015114085A (ru) 2016-11-20
CN104945394A (zh) 2015-09-30
EP2900664A4 (en) 2016-03-09
TW201412732A (zh) 2014-04-01
SG11201500145TA (en) 2015-02-27
JP6310923B2 (ja) 2018-04-11
CN104945394B (zh) 2017-12-05
JP2015531354A (ja) 2015-11-02
ES2660642T3 (es) 2018-03-23
AU2013324779B2 (en) 2015-10-08
EP2900664B1 (en) 2017-12-13
KR20150060610A (ko) 2015-06-03
MY171497A (en) 2019-10-15
CA2881260A1 (en) 2014-04-03
RU2646599C2 (ru) 2018-03-06
TWI561520B (en) 2016-12-11
US9403814B2 (en) 2016-08-02
HK1207081A1 (en) 2016-01-22
US20150239877A1 (en) 2015-08-27
BR112015002979A2 (pt) 2017-07-04
ZA201500290B (en) 2016-10-26
PL2900664T3 (pl) 2018-06-29
CA2881260C (en) 2020-10-27

Similar Documents

Publication Publication Date Title
US10662198B2 (en) Polymorphic form of compound, preparation method and use thereof
KR101424013B1 (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법
CN103724339B (zh) 二氢嘧啶衍生物的晶型
US20040229777A1 (en) Crystalline phases of a potent HCV inhibitor
JP5687291B2 (ja) 強力なｈｃｖ阻害剤の結晶塩
CN105859708B (zh) 二氢嘧啶衍生物的盐及其在药物中的应用
JP2014144916A (ja) ２−アシルアミノチアゾール化合物の結晶
CN104098570A (zh) 替卡格雷晶型及其制备方法和用途
CN106674294A (zh) 吡喃葡萄糖基衍生物的结晶形式
CN106008277A (zh) 一种新型二甲双胍盐酸盐及其制备方法
TW200526205A (en) Nitrogen-containing heterocyclic compound, and medicine containing such compound as effective ingredient
CN116162089B (zh) 嘧啶基抗病毒化合物的制备与使用方法
TW202136237A (zh) RORγt抑制劑及其製備方法和用途
CN105308043B (zh) 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CN111909202B (zh) 尼莫地平磷酸酯衍生物、其药物组合物及其用途
HK1207081B (en) Crystalline forms of dihydropyrimidine derivatives
WO2015109925A1 (zh) 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
HK40077414B (zh) 一种嘧啶甲酰胺类化合物及其应用
WO2022127909A1 (zh) 一种嘧啶甲酰胺类化合物及其应用
BR122025013926A2 (pt) Ácidos carboxílicos de pirazolo piperidina substituídos, seu processo de preparação e medicamento
HK40081347B (zh) 作为pcsk9抑制剂的新化合物
WO2013103004A1 (ja) （２ｅ）－３－（１ｈ－インダゾール－３－イル）－ｎ－（３－メトキシフェニル）－ｎ－［３－（メチルスルホニル）プロピル］ブト－２－エンアミドの結晶形
JPH02290878A (ja) ベンゾチエノ（フロ）ピリジン誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Crystal form of dihydropyrimidine derivatives

Effective date of registration: 20161207

Granted publication date: 20151014

Pledgee: China Development Bank Co.

Pledgor: SUNSHINE LAKE PHARMA Co.,Ltd.

Registration number: 2016990001089

PLDC Enforcement, change and cancellation of contracts on pledge of patent right or utility model
PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20230606

Granted publication date: 20151014

Pledgee: China Development Bank Co.

Pledgor: SUNSHINE LAKE PHARMA Co.,Ltd.

Registration number: 2016990001089

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.